Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.37 |
| ▸ | CTSD | P07339 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362554 | 0.85 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL11894244 | 0.79 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL11894245 | 0.79 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL10326217 | 0.79 | BACE1 (0.34) | BACE1BACE2CTSD | |
| SCHEMBL361836 | 0.78 | CHRNA1 (0.34) | BACE1 | |
| SCHEMBL361433 | 0.77 | BACE1 (0.35) | BACE1BACE2CTSD | |
| SCHEMBL360988 | 0.76 | BACE1 (0.37) | BACE1BACE2CTSD | |
| SCHEMBL10324640 | 0.73 | BACE1 (0.36) | BACE1BACE2CTSD | |
| SCHEMBL361961 | 0.73 | BACE1 (0.35) | BACE1BACE2CTSD | |
| SCHEMBL27854041 | 0.72 | BACE1 (0.36) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284284-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2016-03-15 | — | — | US | disclosed |
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-09-11 | — | — | US | disclosed |
| EP-2766358-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013054291-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885CTSD 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.